Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Jacksonville, Florida: 22-002971
NCT ID: NCT06401889
Sponsor Protocol Number: MC220302
About this study
This project will be a pilot study aiming to describe the change of skin quality after initiation of Aromatase Inhibitor therapy in Breast Cancer survivors through use of VISIA CA technology and skincare intervention.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Female ≥ 18 years.
- Postmenopausal women suitable to receive aromatase inhibitor as per physician’s discretion.
- Histologically confirmed adenocarcinoma of the breast stage 0-III with estrogen receptor (ER) and/or progesterone receptor (PR) positive per ASCO/CAP guideline and any human epidermal growth factor receptor 2 (HER2).
- Patients must not have received any prior chemotherapy, or endocrine therapy for their current breast cancer. Patients who received tamoxifen or raloxifene or another agent for prevention of breast cancer may be included.
- Patients willing to avoid any facial procedures including facials, neurotoxin injections, fillers, or lasers during study period
- Willing and able to provide consent.
Exclusion Criteria:
- Patients who have previously taken AIs.
- Patients using prescription tretinoin, neurotoxin injections, fillers, facial lasers, microneedling, or facials within 6 months of study consent.
Note: Other protocol defined Inclusion/Exclusion Criteria may apply.
Eligibility last updated 2/01/2024. Questions regarding updates should be directed to the study team contact.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
Contact |
Jacksonville, Fla.
Mayo Clinic principal investigator Leila Tolaymat, M.D. |
Open for enrollment |
Contact information:
Cancer Center Clinical Trials Referral Office
(855) 776-0015
|
More information
Publications
Publications are currently not available